AUXERIS THERAPEUTICS
Auxeris Therapeutics is a biopharmaceutical company focused on the development and commercialization of medicines to treat a broad range of bone diseases. The company develops drugs to treat fracture repair, spinal fusion, and bone diseases, including osteoporosis. Auxeris Therapeutics was founded in 2002 and is based in St. Louis, Missouri.
AUXERIS THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Medical Pharmaceutical
Founded:
2002-01-01
Address:
St Louis, Missouri, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
1.6 M USD
Similar Organizations
ANGANY
ANGANY is a pharmaceutical company that offers treatment for allergies.
Antidote Therapeutics
It operates in the biotechnology industry.
Grace Therapeutics
Grace Therapeutics is a pharmaceutical company that focuses on drug delivery treatment for rare and orphan diseases.
Merck
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Peroxitech Therapeutics
Peroxitech Therapeutics operates as a biopharmaceutical company.
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2004-01-16 | Ceros Pharmaceuticals | Ceros Pharmaceuticals acquired by Auxeris Therapeutics | N/A |
Investors List
Domain Associates
Domain Associates investment in Series A - Auxeris Therapeutics
RiverVest
RiverVest investment in Series A - Auxeris Therapeutics
More informations about "Auxeris Therapeutics"
Auxeris Therapeutics - Funding, Financials, Valuation & Investors
Auxeris Therapeutics is a biopharmaceutical company focused on the treatment of bone diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. ...See details»
Auxeris Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Auxeris Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, , Drug:AUX-101 (Auxeris Therapeutics, Inc.), AUX-201, AUX-102.See details»
Auxeris Therapeutics Company Profile | Management and
Auxeris Therapeutics, Inc. - is a biopharmaceutical company developing novel approaches to spinal and bone fusion and the treatment of bone-related diseases. Popular Searches. Auxeris …See details»
Auxeris Focusing Products On Bone Loss Prevention, Disease
Apr 12, 2004 Auxeris is developing therapeutics for bone diseases, such as osteoporosis and bone metastasis. The company wants to prevent or reverse bone loss, as opposed to just …See details»
Auxeris Therapeutics - Products, Competitors, Financials, …
Headquarters Location. 4041 Forest Park Avenue . St. Louis, Missouri, 63108, United States. 314-633-1880See details»
Auxeris Therapeutics - Updates, News, Events, Signals & Triggers
Jan 16, 2004 Organization. Auxeris Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Funding Round • Jan 9, 2004. Auxeris …See details»
Auxeris Therapeutics - Overview, News & Similar companies
Auxeris Therapeutics's headquarters are located at 4041 Forest Park Ave, St. Louis, Missouri, 63108, United States What is Auxeris Therapeutics's official website?See details»
Auxeris Therapeutics Inc. - BioCentury Company Profiles - BCIQ
Jun 28, 2004 Auxeris Therapeutics Inc. - BioCentury Company Profiles for the biopharma industrySee details»
Auxeris Therapeutics, Inc. Asset Profile | Preqin
Auxeris Therapeutics, Inc. is a bio-pharmaceutical company engages in the development and commercialization of proprietary breakthrough medicines. Current Investors Domain …See details»
Auxeris Therapeutics Stock Price, Funding, Valuation, Revenue ...
Jan 5, 2004 Auxeris Therapeutics has raised $4.1M over 1 rounds. Auxeris Therapeutics's latest funding round was a Series A for $4.1M on January 5, 2004. Date. Round. Amount. Investors. …See details»
Auxeris Therapeutics CEO, Founder, Key Executive Team, Board of ...
Auxeris Therapeutics has 2 board of directors, including Brian Halak. Name. Firm. Work History. Other Seats. Brian Halak. As part of Domain Associates since 2001, and a Partner since 2006, …See details»
Auxeris Therapeutics - Tech Stack, Apps, Patents & Trademarks
Organization. Auxeris Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. IT Spend by Aberdeen. Edit IT Spend by …See details»
6 Top BioPharma Startups & Companies (St Louis)
Confluence is a contract research organization providing mechanistic enzymology, target validation, characterization, and more. ... Learn more about their finances on Crunchbase. …See details»
AUX-101 (Auxeris Therapeutics, Inc.) - Drug Targets, Indications ...
AUX-101 (Auxeris Therapeutics, Inc.): a Osteogenesis stimulants Drug, Initially developed by Auxeris Therapeutics, Inc., Now, its global highest R&D status is Discontinued, Mechanism: …See details»
Research programme: antiresorptive bone cancer therapy - Auxeris
Auxeris Therapeutics was developing antiresorptive agents for the treatment of bone metastases and cancer. These compounds bind to a cytokine receptor on Research programme: …See details»
Auxeris Therapeutics - Crunchbase
Rumpus Therapeutics is a biopharmaceutical company that offers clinical development, portfolio management & research on pediatric diseases. Auxeris Therapeutics and Rumpus …See details»
AUX-201 - Drug Targets, Indications, Patents - Synapse
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»
PTC Therapeutics Enters into a Global License and Collaboration ...
7 hours ago About PTC Therapeutics, Inc. PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that …See details»
Research programme: antiresorptive bone cancer therapy - Auxeris
Auxeris Therapeutics was developing antiresorptive agents for the treatment of bone metastases and cancer. These compounds bind to a cytokine receptor on ... If your organization has a …See details»